Cargando…

Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma

BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Yu, Weixin, He, Mingqing, Huang, Yan, Wang, Mingyue, Zhu, Jinzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317466/
https://www.ncbi.nlm.nih.gov/pubmed/30643433
http://dx.doi.org/10.2147/OTT.S189425
_version_ 1783384748883705856
author Wang, Yu
Yu, Weixin
He, Mingqing
Huang, Yan
Wang, Mingyue
Zhu, Jinzhou
author_facet Wang, Yu
Yu, Weixin
He, Mingqing
Huang, Yan
Wang, Mingyue
Zhu, Jinzhou
author_sort Wang, Yu
collection PubMed
description BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. METHODS: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. RESULTS: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all P<0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, P=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, P<0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (P=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). CONCLUSION: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy.
format Online
Article
Text
id pubmed-6317466
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63174662019-01-14 Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma Wang, Yu Yu, Weixin He, Mingqing Huang, Yan Wang, Mingyue Zhu, Jinzhou Onco Targets Ther Original Research BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. METHODS: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. RESULTS: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all P<0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, P=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, P<0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (P=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). CONCLUSION: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy. Dove Medical Press 2018-12-31 /pmc/articles/PMC6317466/ /pubmed/30643433 http://dx.doi.org/10.2147/OTT.S189425 Text en © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Yu
Yu, Weixin
He, Mingqing
Huang, Yan
Wang, Mingyue
Zhu, Jinzhou
Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title_full Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title_fullStr Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title_full_unstemmed Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title_short Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
title_sort serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317466/
https://www.ncbi.nlm.nih.gov/pubmed/30643433
http://dx.doi.org/10.2147/OTT.S189425
work_keys_str_mv AT wangyu serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma
AT yuweixin serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma
AT hemingqing serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma
AT huangyan serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma
AT wangmingyue serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma
AT zhujinzhou serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma